News
STAY TUNED: ELIXI NEWS FROM THE WORLD
FDA approves first drug for treatment of peanut allergy for children
3 February 2020
FDA has approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] to mitigate allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanuts. Treatment with Palforzia may be initiated in individuals ages 4 through 17 years with a confirmed diagnosis of…
The combination of lopinavir/ritonavir and interferon-beta- 1b shows good results against the Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
23 January 2020
The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) was first described in 2012 and attracted a great international attention due to multiple healthcare associated outbreaks. The disease carries a high case fatality rate of 34.5%, and there is no internationally or nationally recommended…
Enhertu (fam-trastuzumab deruxtecan-nxki), new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies
15 January 2020
The U.S. Food and Drug Administration granted accelerated approval to Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) HER2-positive breast cancer who have…
Padcev (enfortumab vedotin-ejfv), a new type of therapy to treat advanced urothelial cancer
13 January 2020
The U.S. Food and Drug Administration has granted accelerated approval to Padcev (enfortumab vedotin-ejfv), a Nectin-4-directed antibody and microtubule inhibitor conjugate, meaning the drug specifically targets cancer cells – in this case, the cell adhesion molecule Nectin-4, which is highly…
Lynparza (olaparib), already licensed for breast and ovarian cancer,it’s set to become the world’s first precision medicine for prostate cancer.
9 January 2020
A new clinical trial founds Lynparza (olaparib), the MSD and AstraZeneca PARP inhibitor, to slow or stop tumor development in men affected with advanced prostate cancer. Lynparza was found to be effective in over 80% of men with prostate cancer whose tumours had mutations in the BRCA genes. The…
Phorbiplatin, a new “on-site” activated anti-tumor prodrug that effectively kills cancer cells minimizing damage to normal tissues.
9 January 2020
A new anti-cancer chemical compound was found capable of reducing tumour size and weight by up to two-thirds in laboratory tests done by researchers from the City University of Hong Kong that made results recently public. The problem in the fight against cancer is that the drugs used in…
First generics of Gilenya (fingolimod) capsules for the treatment of relapsing forms of multiple sclerosis (MS)
11 December 2019
The U.S. Food and Drug Administration has approved three applications for first generics of Gilenya (fingolimod) capsules for the treatment of relapsing forms of multiple sclerosis (MS) in adult patients. “Approving safe and effective generics so patients have more treatment options continues to be…
MiSight, first contact lens indicated to slow the progression of nearsightedness in children
26 November 2019
The U.S. Food and Drug Administration has approved the first contact lens indicated to slow the progression of myopia (nearsightedness) in children between the ages of 8 and 12 years old at the initiation of treatment. The MiSight contact lens is a single use, disposable, soft contact lens that is…
Descovy (emtricitabine and tenofovir alafenamide) drug to prevent HIV infection
20 November 2019
The U.S. Food and Drug Administration has approved Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg) in at-risk adults and adolescents weighing at least 35kg for HIV-1 pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection from sex, excluding those who have receptive…